KLTO-101, the program covered by the patent, is scheduled to start process development and manufacturing in August 2026.
Greenland Mines plans regulatory interactions before end-2026 for KLTO-202, which has reached GMP manufacturing for ALS and other neuromuscular disorders.
Canada patent covers Klotho gene therapy platform
Greenland Mines received a Canadian patent for its Klotho gene therapy platform targeting cognition, memory, Alzheimer’s, aging-related neurodegeneration.
Patent No. CA3,005,398 covers use of the secreted Klotho splice variant (s-KL) delivered via a nucleic-acid gene therapy approach.
The company said the patent includes 42 granted claims spanning protein expression, delivery methods, and therapeutic use across multiple neurodegenerative indications.
GRML•
